Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase IIb trial of Kangfuxin enteric-coated capsules in mild to moderate active ulcerative colitis
CTR20242308Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Jun 2024
- Countries
- 1
01
Overview
A Phase 2 trial of kangfuxin enteric-coated capsule in autoimmune colitis, sponsored by Hengrui Therapeutics. Started Jun 2024; status: completed.
02
Drugs
kangfuxin enteric-coated capsule
03
Conditions
autoimmune colitis
Beyond the preview
Go deeper on CTR20242308.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20242308.